Mizuho Securities Cuts Price Target on CareDx (CDNA) to $8 Following Allenex Acquisition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
AlloSure™ Shows Promise to Detect Rejection in Transplant Patients with a Simple Blood Test
June 13, 2016 7:30 AM EDTCareDx at the Forefront of Personalized Medicine in Transplantation
CareDx to hold Conference Call on June 13, 2016 at 4pm ET
BRISBANE, Calif., June 13, 2016 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, reported the first results of increased levels of donor-derived cell-free DNA (dd-cfDNA) with acute kidney rejection to the DART study clinical investigators attending the American Transplant Congress. The study demonstrated increased levels of dd-cfDNA in acute rejection using the... More
